Alnylam Pharmaceuticals
(ALNY)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2013 | 12-2012 | 09-2012 | 06-2012 | 03-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,013 | -106,014 | -43,826 | -24,324 | -11,368 |
| Depreciation Amortization | 2,127 | 9,035 | 7,011 | 4,726 | 2,121 |
| Accounts receivable | -454 | 1,364 | -450 | -2,917 | -724 |
| Accounts payable and accrued liabilities | -959 | -1,736 | -707 | -281 | -1,461 |
| Other Working Capital | 3,282 | -8,965 | -23,292 | -40,624 | -24,934 |
| Other Operating Activity | 4,046 | -9,293 | 14,567 | 11,511 | 6,151 |
| Operating Cash Flow | $-971 | $-115,609 | $-46,697 | $-51,909 | $-30,215 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -129,041 | 11,884 | -32,315 | -55,897 | -65,168 |
| PPE Investments | -1,799 | -8,348 | -7,662 | -1,933 | -263 |
| Other Investing Activity | 0 | -162 | -162 | -162 | -162 |
| Investing Cash Flow | $-130,840 | $3,374 | $-40,139 | $-57,992 | $-65,593 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 178,210 | 93,771 | 92,774 | 88,275 | 87,647 |
| Common Stock Repurchased | N/A | -359 | -328 | -328 | -328 |
| Financing Cash Flow | $178,210 | $93,412 | $92,446 | $87,947 | $87,319 |
| Beginning Cash Position | 51,405 | 70,228 | 70,228 | 70,228 | 70,228 |
| End Cash Position | 97,804 | 51,405 | 75,838 | 48,274 | 61,739 |
| Net Cash Flow | $46,399 | $-18,823 | $5,610 | $-21,954 | $-8,489 |
| Free Cash Flow | |||||
| Operating Cash Flow | -971 | -115,609 | -46,697 | -51,909 | -30,215 |
| Capital Expenditure | -1,799 | -8,348 | -7,662 | -1,933 | -263 |
| Free Cash Flow | -2,770 | -123,957 | -54,359 | -53,842 | -30,478 |